Dissolution Trend at 12 Months and a Requested Shelf-Life Extension
You are QP for a solid dosage manufacturer. A modified-release tablet has a 24-month shelf life and a dissolution specification of not less than 70% at 60 minutes. Long-term stability at 25 °C/60% RH for three batches shows release values of 88-92%; at 6 months 82-85%; at 12 months 76%, 74% and 75%, with individual units at 71% and 72%. Two of the three batches show the same downward trend; the third is flat at 84%. All results remain within specification. About 9,000 packs from the 12-month time point are in the market, and a further 4,000 packs are in your warehouse with 8-14 months of shelf life remaining. Meanwhile, regulatory affairs wants to extend a second strength of the same product from 24 to 36 months, based on 18 months of long-term data and 6 months of accelerated data with no significant change. The commercial team would like both the market stock and the extension approved before quarter end.
1. Do you take market action now? Give your reasoning and the immediate steps.
Read the worked answer
Not an immediate recall: every result is within specification, and a recall of compliant stock would be disproportionate. But the trend is a stability signal that must be investigated, not merely monitored.
A fall of roughly 14 percentage points in 12 months, consistently across two of three batches, with individual units at 71% and 72% against a 70% limit, leaves very little margin for the remaining shelf life. At the current rate the 24-month batches could fail before expiry. The flat third batch needs explanation: it may indicate a batch-specific factor such as coating or API particle size, or it may simply be less sensitive to the same mechanism.
Immediate steps: open a stability investigation covering the analytical method, dissolution calibration, coating and formulation variables, and storage conditions; review the accelerated and supportive data; check whether the same trend appears in the other strength; and assess whether the current shelf life remains justified. If the trend is confirmed, a shelf-life reduction may be needed, which is a regulatory change and may require notification or variation. Market stock should be reviewed against any reduced expiry, and distribution should not push the oldest packs into the channel while the investigation is open. Document all of this as a QP-level decision.
2. Can you support the shelf-life extension of the second strength to 36 months?
Read the worked answer
No, not on the data described. Eighteen months of long-term data cannot support a 36-month shelf life. Extrapolation is limited, and the generally accepted rule is that a shelf life may be extrapolated by no more than 12 months beyond the period covered by long-term data; 18 months of data could at most support around 30 months, and only if the data show no significant change and the statistical analysis supports it. The commercial target of a quarter-end approval is not a scientific justification.
The dissolution trend in the same product family is directly relevant. A second strength sharing the formulation, coating or process may be expected to behave similarly, and 'no significant change' at 6 months accelerated is not reassuring when long-term dissolution is already drifting in a related product. Before any extension I would want 36 months of long-term data, or a package including at least 24-36 months of long-term data with dissolution profiles, plus a commitment to complete the study, together with a variation supported by the marketing authorisation holder.
The right answer to regulatory affairs is that the extension is not supportable now, and that submitting it on the current data risks a rejection and undermines credibility for the eventual filing.
3. What do you do with the 4,000 packs in the warehouse, and what stability commitments would you require?
Read the worked answer
The warehouse stock should not be released to the market at its current expiry while the investigation is open. Options include holding the stock, assigning a shorter expiry if the data support one, or releasing only the packs with sufficient remaining shelf life once the trend is understood. The decision must be based on the age of each pack and the dissolution margin, not on the need to clear space.
Stability commitments I would require:
- Additional time points and, if necessary, additional batches, with dissolution profiles rather than single-point results.
- Investigation of the mechanism, including coating, curing, API particle size and storage, with corrective action if a process cause is found.
- A review of the accelerated and intermediate conditions, and confirmation that the analytical method is stability-indicating.
- A formal shelf-life reassessment, with a variation and authority approval if the shelf life is reduced or extended.
- A commitment to trend dissolution at every long-term point and to define an alert limit below the specification so that future drift triggers action earlier.
The QP should also confirm that market stock already distributed is being monitored through complaints and returns, and that the conclusion of the investigation, whatever it is, is communicated to the marketing authorisation holder and, where required, the regulator.